Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
Paula I. González-Ericsson(Breast Cancer Research Foundation), Melinda E. Sanders(Vanderbilt University), Xiaopeng Sun(Vanderbilt University Medical Center), Lajos Pusztai(Yale University), Violeta Sánchez(Vanderbilt University), Quanhu Sheng(Cancer Research And Biostatistics), Henry Gómez, Rosa I. Gallagher(George Mason University), Margaret L. Axelrod(Washington University in St. Louis), Kim Blenman(Medical University of South Carolina), Justin M. Balko(Vanderbilt University Medical Center), Na Luo(Shenzhen Maternity and Child Healthcare Hospital), Julia D. Wulfkhule(George Mason University), Emanuel Petricoin(George Mason University)
Cited by 92
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830